- Japanese generic market set to expand rapidly, driven by government commitment to achieving sustainable high-quality healthcare
- Sandoz Japan plans 70 new launches over next six years, which will account
for ~40% of total sales by 2022 - Growth drivers will include oncology, CNS and biosimilars
Tokyo, February 8, 2017 – Sandoz plans to double sales in Japan over the 2015 to 2022 period, as part of its long-term strategic plan to help drive access to hiqh-quality medicines in the Japanese market …